High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients
Elena Yeregui(Institut de Recerca Biomèdica Catalunya Sud), Anna Rull(Institut de Recerca Biomèdica Catalunya Sud), Yolanda M. Pacheco(Instituto de Biomedicina de Sevilla), María Peraire(Hospital Universitario Son Espases), Carles Perpiñán, Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Andra Ceausu(Hospital Universitari Joan XXIII de Tarragona), Jenifer Masip(Hospital Universitari Joan XXIII de Tarragona), Judit Vidal‐González(Vall d'Hebron Institut de Recerca), Josep Mallolas(Hospital Clínic de Barcelona), Alexy Inciarte(Universitat de Barcelona), Laia Reverté(Institute for Research and Technology in Food and Agriculture), Vicenç Falcó(Universitat Autònoma de Barcelona), Peré Domingo(Hospital de Sant Pau), Consuelo Viladés(Hospital Universitario Fundación Jiménez Díaz), Montserrat Vargas(Hospital Universitari Joan XXIII de Tarragona), Sergi Veloso, Verònica Alba, Joaquim Peraire(Instituto de Salud Carlos III), Anna Martí(Institut de Recerca Biomèdica Catalunya Sud)
Cited by 30
Related Papers
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143
Relationship between current level of immunodeficiency and non‐acquired immunodeficiency syndrome‐defining malignancies
|Cancer|2010|141
Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa
|Nature Communications|2019|120
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
|The Lancet HIV|2021|110
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
|Clinical Infectious Diseases|2017|103